Promising methods for the treatment of dyslipidemia in patients with NAFLD

Abstract

Non-alcoholic fatty liver disease (NAFLD), according to forecasts of the World Health Organization, by 2020 it will take the 1st place among all liver diseases., Liver transplantation in patients with cirrhosis in the outcome of NAFLD already takes 2nd place after liver cirrhosis of viral etiology. In patients with NAFLD, mortality in the 1st month after surgery significantly exceeds this indicator in case of liver cirrhosis of a different etiology, and there is an increased risk of other complications of liver transplantation, such as sepsis, transplant rejection and cardiovascular pathology. Specific diagnostic criteria and standard therapy of NAFLD, in practice, does not exist, most likely the diagnosis of NAFLD - “diagnosis of exclusion.” Despite the high prevalence of NAFLD to date, the problem of its effective therapy has not been solved. None of the drugs used in the treatment of NAFLD has a high evidence base. Correction of body weight, changes in food addiction, physical activity are the most effective measures preventing the development of NAFLD and elimination of those negative metabolic processes that are predictors of development of severe forms of type 2 diabetes and high risks of cardiovascular diseases.